AU2019395282A1 - Organophosphorus-substituted compounds as c-MET inhibitors and therapeutic uses thereof - Google Patents

Organophosphorus-substituted compounds as c-MET inhibitors and therapeutic uses thereof Download PDF

Info

Publication number
AU2019395282A1
AU2019395282A1 AU2019395282A AU2019395282A AU2019395282A1 AU 2019395282 A1 AU2019395282 A1 AU 2019395282A1 AU 2019395282 A AU2019395282 A AU 2019395282A AU 2019395282 A AU2019395282 A AU 2019395282A AU 2019395282 A1 AU2019395282 A1 AU 2019395282A1
Authority
AU
Australia
Prior art keywords
alkyl
compound
group
pharmaceutically acceptable
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2019395282A
Other languages
English (en)
Inventor
Michael John COSTANZO
Michael Nicholas Greco
Michael Alan Green
Jirong Peng
Don Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beta Pharma Inc
Original Assignee
Beta Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beta Pharma Inc filed Critical Beta Pharma Inc
Publication of AU2019395282A1 publication Critical patent/AU2019395282A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/50—Organo-phosphines
    • C07F9/5004—Acyclic saturated phosphines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/32—Esters thereof
    • C07F9/3205—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/3211—Esters of acyclic saturated acids which can have further substituents on alkyl

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2019395282A 2018-12-14 2019-12-14 Organophosphorus-substituted compounds as c-MET inhibitors and therapeutic uses thereof Abandoned AU2019395282A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862779960P 2018-12-14 2018-12-14
US62/779,960 2018-12-14
PCT/US2019/066414 WO2020124060A1 (en) 2018-12-14 2019-12-14 Organophosphorus-substituted compounds as c-met inhibitors and therapeutic uses thereof

Publications (1)

Publication Number Publication Date
AU2019395282A1 true AU2019395282A1 (en) 2021-07-08

Family

ID=71077551

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019395282A Abandoned AU2019395282A1 (en) 2018-12-14 2019-12-14 Organophosphorus-substituted compounds as c-MET inhibitors and therapeutic uses thereof

Country Status (15)

Country Link
US (1) US12258365B2 (https=)
EP (1) EP3893872B1 (https=)
JP (1) JP2022513215A (https=)
KR (1) KR20210111779A (https=)
CN (1) CN113412112B (https=)
AU (1) AU2019395282A1 (https=)
BR (1) BR112021011547A2 (https=)
CA (1) CA3122575A1 (https=)
EA (1) EA202191541A1 (https=)
IL (1) IL283589A (https=)
MX (1) MX2021006982A (https=)
SG (1) SG11202105872RA (https=)
TW (1) TW202039500A (https=)
WO (1) WO2020124060A1 (https=)
ZA (1) ZA202104000B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116969955B (zh) * 2023-09-25 2023-12-19 中国药科大学 一种[1,2,4]三唑[4,3-b]哒嗪类化合物及其制法与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20170103T1 (hr) 2005-12-21 2017-03-24 Janssen Pharmaceutica N.V. Triazolopiridazini kao modulatori tirozin kinaze
NL2000613C2 (nl) * 2006-05-11 2007-11-20 Pfizer Prod Inc Triazoolpyrazinederivaten.
US20110039856A1 (en) * 2007-11-29 2011-02-17 Pfizer Inc. Polymorphs of a c-met/hgfr inhibitor
UY32049A (es) 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
EA030141B1 (ru) 2009-12-31 2018-06-29 Хатчисон Медифарма Лимитед Определенные триазолопиридины и триазолопиразины, их композиции и способы их применения
ES2598530T3 (es) 2010-07-14 2017-01-27 Betta Pharmaceuticals Co., Ltd. Nuevos derivados heterocíclicos condensados útiles como inhibidores de la tirosina quinasa c-Met
TWI520962B (zh) * 2012-06-29 2016-02-11 As the c-Met tyrosine kinase inhibitors novel fused pyridine derivatives
CN103122000B (zh) * 2012-09-03 2013-12-25 中美冠科生物技术（太仓）有限公司 用作抗肿瘤药物的高选择性的c-Met激酶抑制剂
ES2877799T3 (es) * 2015-12-31 2021-11-17 Shanghai Pharmaceuticals Holding Co Ltd Sal de derivado de quinolina, formas polimórficas de la misma, métodos de preparación de la misma, composición y aplicaciones

Also Published As

Publication number Publication date
CN113412112A (zh) 2021-09-17
EP3893872B1 (en) 2024-07-17
KR20210111779A (ko) 2021-09-13
CN113412112B (zh) 2024-06-11
EA202191541A1 (ru) 2022-01-21
TW202039500A (zh) 2020-11-01
WO2020124060A1 (en) 2020-06-18
SG11202105872RA (en) 2021-07-29
EP3893872A4 (en) 2022-08-10
EP3893872A1 (en) 2021-10-20
US12258365B2 (en) 2025-03-25
MX2021006982A (es) 2021-09-10
ZA202104000B (en) 2022-08-31
BR112021011547A2 (pt) 2021-08-31
CA3122575A1 (en) 2020-06-18
US20220064194A1 (en) 2022-03-03
IL283589A (en) 2021-07-29
JP2022513215A (ja) 2022-02-07

Similar Documents

Publication Publication Date Title
CN112094269B (zh) 一类饱和六元环并杂环类化合物、制备方法和用途
CA3063469C (en) Kras g12c inhibitors and methods of using the same
CA2907502C (en) Benzimidazolone derivatives as bromodomain inhibitors
KR20220042431A (ko) 헤테로시클릭 rip1 키나제 억제제
TWI897895B (zh) 雜環ｒｉｐ１抑制性化合物
CN111961034A (zh) 用作ret激酶抑制剂的化合物及其应用
CN105121443A (zh) 蛋白激酶抑制剂
JP7801223B2 (ja) Ｃｄ２０６モジュレーター、その使用、および調製方法
CN113045559A (zh) 一种二芳基脲类PI3Kα/mTOR双靶点抑制剂及其药物组合物和应用
CN115677730B (zh) 8-氧-3-氮杂二环[3.2.1]辛烷类化合物或其盐及其制备方法和用途
CN115340559A (zh) Shp2磷酸酶杂环类抑制剂的制备及其应用
JP2024527044A5 (https=)
CN118632843A (zh) 一种吡啶类衍生物及其用途
EP3893872B1 (en) Organophosphorus-substituted compounds as c-met inhibitors and therapeutic uses thereof
WO2025087267A1 (zh) 一种含有噻唑基的哌啶并嘧啶类衍生物、其制备方法及其医药上的应用
WO2023011446A1 (zh) 一种新型磺酰胺类menin-MLL相互作用抑制剂、其制备方法及医药用途
EA050883B1 (ru) 8-окса-3-азабицикло[3.2.1]октановые соединения или их соли, способ их получения и применение
CN118290443A (zh) 色酮并杂环类化合物及其制备方法和用途
CN115515958A (zh) 一种新型磺酰胺类menin-MLL相互作用抑制剂、其制备方法及医药用途
CN115960109A (zh) 稠环类shp2磷酸酶抑制剂的制备及其应用
CN115572260A (zh) 芳基醚类化合物及其用途

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period